Quantum BioPharma’s Lucid-MS Clears Phase 1 Trial

Quantum BioPharma has successfully completed its Phase 1 clinical trial evaluating Lucid-21-302 (Lucid-MS), a first-in-class neuroprotective treatment for multiple sclerosis (MS). The randomized, double-blind, placebo-controlled study confirmed that Lucid-MS was well-tolerated with no serious adverse events. A final safety review committee meeting concluded that the drug showed a strong safety profile in healthy participants. Unlike traditional MS treatments that focus on immune modulation, Lucid-MS works by directly stabilizing the myelin sheath, potentially preventing demyelination—a key factor in disease progression.

Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs, called the milestone a major step toward advancing Lucid-MS to the next stage of development. CEO Zeeshan Saeed emphasized the drug’s potential to revolutionize MS treatment by offering a new approach focused on myelin protection rather than immune suppression. With Phase 1 successfully completed, Quantum BioPharma is preparing to launch a Phase 2 trial in MS patients, bringing the company one step closer to potential regulatory approval and commercialization.